Publication | Closed Access

Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose

Drug SafetyOncologyPharmacokinetic ModelingQsar ModelingObserved Effect LevelMedicinePreclinical Drug EvaluationClinical TrialsToxicologyDosimetryPharmacotherapyPharmacodynamic ModelingPharmacologyPharmacokineticsDrug Discovery